Literature DB >> 15107620

ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?

Sarah E Seton-Rogers1, Joan S Brugge.   

Abstract

Amplification and overexpression of ErbB2 (HER2/Neu) is one of the most common alterations associated with breast cancer. Activation of ErbB2 via homodimerization in a non-transformed human mammary epithelial cell line, MCF-10A, in basement membrane cultures leads to formation of proliferative structures that share properties with non-invasive early stage lesions. Recently, we have shown that activation of ErbB2 homodimers combined with expression of transforming growth factor (TGF)-beta induces invasive and migratory activity in MCF-10A cells. In this system, migration requires inputs from numerous cellular pathways. We discuss this data and a model for migration induced by ErbB2 and TGF-beta. Concurrent studies by other groups have also shown that ErbB2 and TGF-beta can cooperate to increase metastatic and invasive behavior in murine mammary tumors. Here we discuss these studies and the potential implications of this research on breast cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15107620

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  12 in total

Review 1.  Roles for growth factors in cancer progression.

Authors:  Esther Witsch; Michael Sela; Yosef Yarden
Journal:  Physiology (Bethesda)       Date:  2010-04

2.  Dbl oncogene expression in MCF-10 A epithelial cells disrupts mammary acinar architecture, induces EMT and angiogenic factor secretion.

Authors:  Cristina Vanni; Marzia Ognibene; Federica Finetti; Patrizia Mancini; Sara Cabodi; Daniela Segalerba; Maria Rosaria Torrisi; Sandra Donnini; Maria Carla Bosco; Luigi Varesio; Alessandra Eva
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis.

Authors:  Kenna R Mills Shaw; Carolyn N Wrobel; Joan S Brugge
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

4.  Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.

Authors:  Peter C Gray; Gidi Shani; Kevin Aung; Jonathan Kelber; Wylie Vale
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

5.  Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth.

Authors:  A Emde; C-R Pradeep; D A Ferraro; N Ben-Chetrit; M Sela; B Ribba; Z Kam; Y Yarden
Journal:  Oncogene       Date:  2010-12-06       Impact factor: 9.867

6.  TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch.

Authors:  Irwin M Liu; Stephen H Schilling; Kristin A Knouse; Lisa Choy; Rik Derynck; Xiao-Fan Wang
Journal:  EMBO J       Date:  2008-12-18       Impact factor: 11.598

Review 7.  Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

Authors:  Antoinette R Tan; Gabriela Alexe; Michael Reiss
Journal:  Breast Cancer Res Treat       Date:  2008-10-09       Impact factor: 4.872

8.  Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms.

Authors:  Jason R Neil; Kyle M Johnson; Raphael A Nemenoff; William P Schiemann
Journal:  Carcinogenesis       Date:  2008-08-25       Impact factor: 4.944

9.  Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance.

Authors:  Chang-Yuan Wei; Qi-Xing Tan; Xiao Zhu; Qing-Hong Qin; Fei-Bai Zhu; Qin-Guo Mo; Wei-Ping Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 10.  Signaling cross-talk between TGF-beta/BMP and other pathways.

Authors:  Xing Guo; Xiao-Fan Wang
Journal:  Cell Res       Date:  2009-01       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.